Helios Israel

Helios Israel, operating as Interlune, is a space-resource company founded in 2018 focused on the commercialization of lunar resources. The company is developing processes for *in-situ* resource utilization (ISRU), with a primary focus on extracting Helium-3 from lunar regolith. Interlune intends to supply this Helium-3 to Earth-based industries, including quantum computing, national security, clean energy (fusion power), and advanced medical imaging – specifically hyperpolarized Helium-3 MRI for improved lung diagnostics.

Interlune’s core intellectual property centers around novel, patent-pending machinery and processes designed for resource detection and extraction in space. A key differentiator is the development of equipment that is significantly smaller, lighter, and requires up to ten times less power than competing systems, enabling deployment via a single launch. The company highlights a commitment to responsible lunar resource management, emphasizing preservation and equitable access alongside economic benefit.

Recent media coverage in publications like CNET, The Washington Post, and Forbes (dated September-November 2025) indicates significant progress and commercial traction, including a reported major purchase agreement for lunar Helium-3 valued at $20 million per kilogram. This positions Interlune as a leading contender in the emerging space-resource market, aiming to be the first company to commercially harvest and deliver resources from the Moon to Earth.